Tuzistra XR codeine polistirex/chlorpheniramine polistirex regulatory update

FDA approved an NDA from Tris for Tuzistra XR for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults. Partner Vernalis hopes to launch Tuzistra XR ahead of the 2015-16 cough-cold season. Vernalis has exclusive, North American rights to the product from Tris under a February 2012 deal to commercialize up to 6 reformulated prescription cough and cold products using Tris’ OralXR+ extended-release formulation technology (see BioCentury, Feb. 13, 2012 & July 5, 2014). ...